Trial Profile

An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Latanoprost (Primary)
Indications Angle-closure glaucoma
Focus Proof of concept; Therapeutic Use
Sponsors Eyenovia

Most Recent Events

28 Nov 2018 Results presented in an Eyenovia media release.
28 Nov 2018 According to an Eyenovia media release, results from this study were published in the November 2018 issue of the peer-review journal Clinical Ophthalmology.
13 Nov 2018 According to an Eyenovia media release, data from the study have been accepted for publication by the peer-reviewed journal Clinical Ophthalmology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com